HAVCR2 and acute myeloid leukemia: Regardless of EFS or OS, high Tim‐3 is an independent risk factor (Figure 6D, E), which is consistent with the results of the TCGA‐AML and GEO datasets described above, suggesting that Tim‐3 of CD34+ leukemia cells could be a potential therapeutic target.